A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

NCT02508467 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Fisogatinib (BLU-554)

Sponsor

Blueprint Medicines Corporation